SCHEMBL3011010

SCHEMBL3011010

O=S(=O)(c1cc(Cl)ccc1Cl)N1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
USP2 O75604 1/20 0.41
LMNA P02545 5/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
CNR1 P21554 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PKM P14618 1/20 0.39
GPR183 P32249 1/20 0.39
ATM Q13315 1/20 0.38
KDM2B Q8NHM5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015825 0.96 ALDH1A1 (0.44) ALDH1A1L3MBTL1TSHRALOX15USP2
SCHEMBL3009899 0.94 ALDH1A1 (0.44) ALDH1A1L3MBTL1TSHRALOX15USP2
SCHEMBL3011722 0.92 TRPV4 (0.44) ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2
SCHEMBL2999037 0.91 ALDH1A1 (0.46) ALDH1A1L3MBTL1TSHRALOX15USP2
SCHEMBL3012911 0.91 ALDH1A1 (0.48) ALDH1A1L3MBTL1TSHRALOX15USP2
SCHEMBL3008554 0.90 KMT2A (0.45) ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2
SCHEMBL3652491 0.90 ALDH1A1 (0.39) ALDH1A1L3MBTL1TSHRALOX15USP2
SCHEMBL3015184 0.90 ALDH1A1 (0.47) ALDH1A1L3MBTL1TSHRLMNAMAPT
SCHEMBL3007155 0.90 TRPV4 (0.43) ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2
SCHEMBL3010380 0.89 ALDH1A1 (0.44) ALDH1A1L3MBTL1TSHRALOX15USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885L3MBTL1 1847/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.